Want to see QNRX full AI Analyst Report?
Top Page
Quoin Pharmaceuticals
(NASDAQ:QNRX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$4.00
▼(-21.10% Downside)
Action:Reiterated
Date:10/20/26
The score is held down primarily by very weak financial performance (no revenue, widening losses, and accelerating cash burn with shrinking equity), reinforced by a bearish technical setup (price below key moving averages and negative MACD). Offsetting these risks, corporate events provide meaningful upside optionality via positive clinical/regulatory momentum and improved financing runway, but not enough to overcome the current fundamental and trend weakness.
Positive Factors
Clinical evidence
QRX003 has generated encouraging early efficacy and safety signals across a pediatric case and interim Phase 2/3 results. While not definitive, this evidence supports development momentum and the possibility of addressing a severe condition with no approved Netherton-specific treatment.
Negative Factors
No commercial revenue
Quoin remains entirely dependent on development-stage assets rather than an established commercial product base. With no reported revenue, the company has not demonstrated market monetization, making future value dependent on successful trials, approvals, and eventual launch execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical evidence
QRX003 has generated encouraging early efficacy and safety signals across a pediatric case and interim Phase 2/3 results. While not definitive, this evidence supports development momentum and the possibility of addressing a severe condition with no approved Netherton-specific treatment.
Read all positive factors
Quoin Pharmaceuticals (QNRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.33M
Dividend YieldN/A
Average Volume (3M)39.20K
Price to Earnings (P/E)―
Beta (1Y)-0.61
Revenue GrowthN/A
EPS Growth98.98%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-14.89
Shares Outstanding4,804,161
10 Day Avg. Volume27,638
30 Day Avg. Volume39,204
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-1.60
Enterprise Value/Market Cap-0.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit42.44
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$21.40Price Target Upside322.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-6.08
Revenue Forecast (FY)N/A
Quoin Pharmaceuticals Business Overview & Revenue Model
Company Description
Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulat...
Quoin Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 13, 2024
(Q4-2023)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The earnings call reflects a generally positive outlook for Quoin Pharmaceuticals, with significant progress in clinical trials, strong commercial partnerships, and a solid financial position. However, challenges remain in managing cash burn and executing M&A strategies.Positive Updates
Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Negative Updates
Net Loss and Cash Burn
Despite a decrease in net loss from $9.4 million in 2022 to $8.7 million in 2023, Quoin still faces financial challenges with ongoing R&D expenses and a net loss of $2 million in Q4 2023.
Read all updates
Q4-2023 Updates
Positive
Negative
Transformational Year for Quoin
2023 was a transformational year for Quoin, marked by the release of the first-ever clinical data from a trial in Netherton syndrome subjects under an open IND with the FDA. The initial data was positive across several clinical endpoints with no safety signals.
Read all positive updates
Company Guidance
During the Q4 2023 earnings call for Quoin Pharmaceuticals (QNRX), key guidance included updates on clinical trials for QRX003, a potential treatment for Netherton syndrome. The company implemented several FDA-cleared protocol amendments, including increasing study size, altering dosing frequency, and lowering eligibility age to 14 years. They have 9 commercial partnerships covering 61 countries and completed a $6.5 million public offering, with an $8 million equity line of credit to extend their cash runway into the second half of 2026. Despite a net loss of $8.7 million for 2023, Quoin remains the only company with an open IND for Netherton syndrome, positioning itself for a pivotal year in 2024.Quoin Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
42
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -25.43K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -18.88M | -15.70M | -8.86M | -8.58M | -8.56M | -20.27M |
| Net Income | -18.76M | -15.80M | -8.96M | -8.69M | -9.38M | -21.46M |
Balance Sheet | ||||||
| Total Assets | 11.97M | 20.39M | 15.71M | 12.17M | 14.46M | 9.36M |
| Cash, Cash Equivalents and Short-Term Investments | 10.80M | 3.82B | 14.06M | 10.69M | 12.85M | 7.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 8.04M | 7.27M | 6.50M | 6.51M | 7.05M | 8.70M |
| Stockholders Equity | 3.93M | 13.12M | 9.20M | 5.66M | 7.41M | 657.03K |
Cash Flow | ||||||
| Free Cash Flow | -15.39M | -13.54M | -7.86M | -7.86M | -8.73M | -6.35M |
| Operating Cash Flow | -15.39M | -13.54M | -7.86M | -7.86M | -8.48M | -5.72M |
| Investing Cash Flow | -610.32K | -4.28M | -1.89M | 2.19M | -10.15M | -625.00K |
| Financing Cash Flow | 18.19M | 18.01M | 10.97M | 5.22M | 14.01M | 13.50M |
Quoin Pharmaceuticals Technical Analysis
Negative
5.07
Price Trends
5.44
Negative
5.01
Negative
6.09
Negative
Market Momentum
-0.39
Negative
36.28
Neutral
66.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNRX, the sentiment is Negative. The current price of 5.07 is above the 20-day moving average (MA) of 4.22, below the 50-day MA of 5.44, and below the 200-day MA of 6.09, indicating a bearish trend. The MACD of -0.39 indicates Negative momentum. The RSI at 36.28 is Neutral, neither overbought nor oversold. The STOCH value of 66.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNRX.
Quoin Pharmaceuticals Risk Analysis
Quoin Pharmaceuticals disclosed 57 risk factors in its most recent earnings report. Quoin Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Quoin Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $8.33M | -0.28 | -304.87% | ― | ― | 98.98% | |
47 Neutral | $12.81M | -0.31 | -1693.21% | ― | ― | 45.78% | |
41 Neutral | $2.47M | -0.01 | -372.86% | ― | ― | 53.95% | |
40 Underperform | $4.74M | ― | 762.51% | ― | 135.52% | 85.50% |
* Healthcare Sector Average
QNRX
Quoin Pharmaceuticals
4.15
-7.27
-63.66%
JAGX
Jaguar Animal Health
2.04
-749.84
-99.73%
ADIL
Adial Pharmaceuticals
4.88
-4.04
-45.27%
ALZN
Alzamend Neuro
1.22
-1.39
-53.26%
CLDI
Calidi Biotherapeutics
0.67
-24.61
-97.35%
Quoin Pharmaceuticals Corporate Events
Business Operations and StrategyProduct-Related Announcements
Quoin Showcases QRX003 Pediatric Data in Published Study
Positive
Oct 20, 2026
On October 20, 2026, Quoin Pharmaceuticals announced the online publication of a peer‑reviewed paper in Dermatology and Therapy detailing QRX003, its investigational topical serine protease inhibitor lotion for Netherton Syndrome. The articl...
Business Operations and StrategyRegulatory Filings and Compliance
Quoin Pharmaceuticals Gains EMA Orphan Status for QRX003
Positive
Oct 14, 2026
On October 14, 2026, Quoin Pharmaceuticals announced that the European Medicines Agency granted Orphan Drug Designation to its lead candidate QRX003 for the treatment of Peeling Skin Syndrome. The status provides incentives such as scientific advi...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Quoin Gains FDA Fast Track for QRX003 Skin Therapy
Positive
Sep 22, 2026
On Sept. 22, 2026, Quoin Pharmaceuticals announced that the U.S. Food and Drug Administration granted Fast Track Designation to its lead candidate QRX003 for Peeling Skin Syndrome, marking the first Fast Track status ever awarded for this rare gen...
Business Operations and StrategyRegulatory Filings and Compliance
Quoin Pharmaceuticals Gains FDA Rare Pediatric Designation
Positive
Sep 10, 2026
On September 8, 2026, Quoin Pharmaceuticals reported that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to its lead asset QRX003 for treating Peeling Skin Syndrome. This marks the second such status for QRX003, w...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Quoin Reports Positive Interim QRX003 Netherton Data
Positive
Aug 28, 2026
On August 27, 2026, Quoin Pharmaceuticals entered into a securities purchase agreement with institutional and accredited investors for a private placement of up to $50 million in ADSs, pre-funded warrants and ordinary warrants, with about $30.8 mi...
Executive/Board ChangesShareholder Meetings
Quoin Pharmaceuticals Shareholders Approve Governance and Compensation Changes
Neutral
Aug 20, 2026
At its 2026 Annual General Meeting of Shareholders held on August 20, 2026, Quoin Pharmaceuticals’ investors approved a suite of governance and compensation measures, including the re-election of seven directors and an advisory endorsement o...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.